Tyra Biosciences (TYRA) Enterprise Value (2021 - 2026)

Tyra Biosciences (TYRA) has 7 years of Enterprise Value data on file, last reported at -$85.0 million in Q1 2026.

• Quarterly Enterprise Value rose 15.65% year-over-year to -$85.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$85.0 million (up 15.65% YoY) and the FY2025 annual result came in at -$77.4 million, up 15.85% from the prior year.
• Enterprise Value retreated to -$85.0 million in Q1 2026, from -$77.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$58.0 million in Q4 2023 to a low of -$292.5 million in Q1 2022.
• A 5-year average of -$164.9 million and a median of -$103.9 million in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value slumped 107.98% — and 2023, when it surged 76.91%.
• Tracing TYRA's Enterprise Value over 5 years: stood at -$251.2 million in 2022, then surged by 76.91% to -$58.0 million in 2023, then tumbled by 58.55% to -$92.0 million in 2024, then increased by 15.85% to -$77.4 million in 2025, then declined by 9.78% to -$85.0 million in 2026.
• The last three Enterprise Value figures came in at -$85.0 million (Q1 2026), -$77.4 million (Q4 2025), and -$62.0 million (Q3 2025), per Business Quant data.